Verastem (NASDAQ:VSTM) Shares Gap Up – Time to Buy?

Verastem, Inc. (NASDAQ:VSTM)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $7.45, but opened at $8.00. Verastem shares last traded at $8.7640, with a volume of 10,572,543 shares.

Key Stories Impacting Verastem

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Promising VS-7375 data: Verastem reported robust anti-tumor activity in patients with KRAS G12D-mutated pancreatic, lung and colorectal cancers. The company highlighted a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line or later disease, supporting the drug’s potential ahead of late-stage testing. VS-7375 clinical data
• Positive Sentiment: Substantial funding secured: Verastem priced a $250 million underwritten offering, with proceeds intended to support VS-7375 development and planned late-stage studies. The financing strengthens the company’s balance sheet and extends its ability to advance the program. $250 million offering
• Neutral Sentiment: Planned leadership change: Michael P. Bailey will become president and CEO on January 1, 2027, replacing retiring CEO Daniel Paterson. The transition is planned rather than prompted by an immediate setback, but investors may evaluate Bailey’s ability to execute the company’s late-stage development strategy. CEO transition announcement
• Negative Sentiment: Shareholder dilution: Issuing more than 30.9 million common shares, along with pre-funded warrants, dilutes existing holders. The $8 offering price may also create a near-term reference point for the stock, partially offsetting the positive impact of the clinical update.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised Verastem from a “sell” rating to a “hold” rating in a research note on Sunday, September 27th. Jefferies Financial Group reduced their price objective on shares of Verastem from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, June 23rd. Mizuho set a $13.00 price objective on shares of Verastem and gave the stock an “outperform” rating in a research report on Monday, August 10th. Wolfe Research initiated coverage on shares of Verastem in a research note on Thursday, September 17th. They set an “outperform” rating for the company. Finally, BTIG Research restated a “buy” rating and issued a $18.00 target price on shares of Verastem in a report on Monday, October 5th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Verastem currently has a consensus rating of “Moderate Buy” and an average price target of $13.83.

Verastem Trading Up 17.8%

The firm’s 50-day moving average price is $7.50 and its 200 day moving average price is $5.89. The company has a market cap of $794.66 million, a price-to-earnings ratio of -3.34 and a beta of 0.39. The company has a current ratio of 2.25, a quick ratio of 2.22 and a debt-to-equity ratio of 1.48.

Verastem (NASDAQ:VSTM) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. The company had revenue of $40.08 million for the quarter, compared to the consensus estimate of $22.88 million. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. As a group, equities analysts expect that Verastem, Inc. will post -1.55 EPS for the current year.

Insiders Place Their Bets

In other Verastem news, CEO Dan Paterson sold 44,121 shares of Verastem stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $8.00, for a total value of $352,968.00. Following the completion of the sale, the chief executive officer directly owned 652,712 shares of the company’s stock, valued at approximately $5,221,696. The trade was a 6.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,044 shares of company stock valued at $381,484 over the last ninety days. Insiders own 1.94% of the company’s stock.

Hedge Funds Weigh In On Verastem

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC increased its position in Verastem by 68.7% in the 4th quarter. Armistice Capital LLC now owns 3,536,000 shares of the biopharmaceutical company’s stock valued at $27,298,000 after buying an additional 1,440,000 shares in the last quarter. Foresite Capital Management VI LLC raised its stake in shares of Verastem by 19.9% in the fourth quarter. Foresite Capital Management VI LLC now owns 3,135,120 shares of the biopharmaceutical company’s stock worth $24,203,000 after purchasing an additional 520,000 shares during the last quarter. AIGH Capital Management LLC purchased a new stake in shares of Verastem in the first quarter worth approximately $10,600,000. Opaleye Management Inc. bought a new position in shares of Verastem in the second quarter valued at approximately $6,876,000. Finally, Exome Asset Management LLC lifted its holdings in shares of Verastem by 58.5% in the first quarter. Exome Asset Management LLC now owns 636,700 shares of the biopharmaceutical company’s stock valued at $3,375,000 after purchasing an additional 234,957 shares in the last quarter. Institutional investors own 88.37% of the company’s stock.

About Verastem

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer.